0001279569-14-001618.txt : 20141015 0001279569-14-001618.hdr.sgml : 20141009 20141009124943 ACCESSION NUMBER: 0001279569-14-001618 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20141009 FILED AS OF DATE: 20141009 DATE AS OF CHANGE: 20141009 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aptose Biosciences Inc., (formerly LORUS THERAPEUTICS INC.) CENTRAL INDEX KEY: 0000882361 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32001 FILM NUMBER: 141149739 BUSINESS ADDRESS: STREET 1: 2 MERIDIAN ROAD STREET 2: . CITY: TORONTO STATE: A6 ZIP: M9W 4Z7 BUSINESS PHONE: 416-798-1200 MAIL ADDRESS: STREET 1: 2 MERIDIAN ROAD CITY: TORONTO STATE: A6 ZIP: M9W 4Z7 FORMER COMPANY: FORMER CONFORMED NAME: LORUS THERAPEUTICS INC DATE OF NAME CHANGE: 19990308 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC PHARMA INC DATE OF NAME CHANGE: 19970113 FORMER COMPANY: FORMER CONFORMED NAME: IMUTEC CORP DATE OF NAME CHANGE: 19950726 6-K 1 aptose6k.htm FORM 6-K

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the Month of October, 2014

Commission File Number 1-32001

Aptose Biosciences Inc.

(formerly Lorus Therapeutics Inc.)

(Translation of registrant’s name into English)

2 Meridian Road, Toronto, Ontario M9W 4Z7

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐ No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82-_______________.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Aptose Biosciences Inc.


Date: October 9, 2014	By:	/s/ “Gregory Chow”
		Gregory Chow
		Senior Vice President and Chief Financial Officer

EXHIBIT INDEX

99.1	Notice Change In Year-End

EX-99.1 2 ex991.htm NOTICE CHANGE IN YEAR-END

Exhibit 99.1

NOTICE CHANGE IN YEAR-END
PART 4.8(3) NATIONAL INSTRUMENT 51-102

(a)

Statement that the reporting issuer has decided to change its year-end.

Lorus Therapeutics Inc. (the “Issuer”) has decided to change its year-end from May 31 to December 31.

(b)

The reason for the change.

The Issuer wishes to change its year end to allow the Issuer to provide continuous disclosure information on a comparable position with its industry peer group.

(c)

The reporting issuer’s old financial year-end.

May 31, 2014

(d)

The reporting issuer’s new financial year-end.

December 31, 2014

(e)

The length and ending date of the periods, including the comparative periods, of the interim and annual financial statements to be filed for the reporting issuer’s transition year and its new financial year.

Annual:

7-month period during transition year ended December 31, 2014 compared to the year ended May 31, 2014

Interims:

Q3 2014 - 4 month period ended September 30, 2014 compared to the 3 month period ended August 31, 2013
Q1 2015 – 3 month period ended March 31, 2015 compared to the 3 month period ended February 28, 2014
Q2 2015 – 3 month period ended June 30, 2015 compared to the 3 month period ended May 31, 2014
Q3 2015 – 3 month period ended September 30, 2015 compared to the 4 month period ended September 30, 2014

(f)

The filing deadlines, prescribed under sections 4.2 and 4.4, for the interim and annual financial statements for the Issuer’s transition year.

	Annual:		Year ended December 31, 2014		Due:	March 31, 2015
	Q3		Interim period ended September 30, 2014		Due:	November 14, 2014

[Remainder of page left intentionally blank]

DATED July 17, 2014

LORUS THERAPEUTICS INC.

	/s/ “Gregory Chow”
	Name: Gregory K. Chow
	Title: Senior Vice President and CFO